Jul. 11, 2012
Ascletis Pharmaceuticals, a US-China JV that made headlines one year ago when it announced $100 million in initial startup capital, declared on July 12, 2012 that it has in-licensed China rights to its first drug candidate, an innovative RNAi molecule, ALN-VSP, from Alnylam Pharma, a leading RNAi therapeutics company. ALN-VSP is a first-in-class, systemically delivered RNAi therapeutic drug for the treatment of liver cancers including hepatocellular carcinoma (HCC), a significant area of unmet need in China. This collaboration provides Ascletis with the exclusive rights to develop and commercialize ALN-VSP in China including Hong Kong, Macau, and Taiwan. Alnylam will retain all rights in the rest of the world, and is eligible to receive milestones and royalties based on product sales.